Conference Coverage
Conference Coverage
CARMELINA confirms linagliptin’s renal, CV safety, but it’s still third-line for type 2 diabetes
SAN FRANCISCO – The study was unusual among other DPP-4 trials in that almost 60% of the patients were older than 65, and 62.3% had impaired renal...
Conference Coverage
Can mindfulness-based cognitive therapy treat migraine?
PHILADELPHIA – Mindfulness-based cognitive therapy for migraine may reduce migraine-related disability, even as the number of headache days and...
Latest News
BMI screening trigger for type 2 diabetes is unreliable for at-risk black, Hispanic adults
SAN FRANCISCO – One risk factor should trigger screening in normal weight.
Conference Coverage
Cellulitis ranks as top reason for skin-related pediatric inpatient admissions
AUSTIN, TX – The median length of stay for patients was 2 days, with a median cost of $6,289.50 for each case.
Conference Coverage
Risk of atrial fibrillation 900% higher with cancer
MELBOURNE –
Conference Coverage
Novel topical psoriasis treatment targets nerve pathways
MILAN – The nonsteroidal investigative drug SNA-120 helped with psoriasis severity, burning, and pain.
Conference Coverage
Subcutaneous marstacimab appears safe in hemophilia A and B
MELBOURNE – Subcutaneous marstacimab produced significant reductions in bleeding rates in hemophilia A and B with reasonable safety and...
Conference Coverage
No reduction in PE risk with vena cava filters after severe injury
MELBOURNE – “Given the cost and risks associated with a vena cava filter, our data suggest that there is no urgency to insert the filter in...
Conference Coverage
CDC: Look for early symptoms of acute flaccid myelitis, report suspected cases
The average age of a patient diagnosed with AFM is 5 years
Conference Coverage
Drug efficacy in phase 2 RA trials often missing in phase 3
MADRID – Meta-analysis of 44 pairs of phase 2 and phase 3 RA trials showed that phase 2 results often overestimate efficacy.